Results 31 to 40 of about 6,997,331 (310)

Safety Profile of Ibrutinib: An Analysis of the WHO Pharmacovigilance Database

open access: yesFrontiers in Pharmacology, 2021
As ibrutinib has become a standard of care in B-cell malignancies in monotherapy or in combination with other agents, definition of its safety profile appears essential.
M. Allouchery   +4 more
semanticscholar   +1 more source

Chitosan encompassed Aniba rosaeodora essential oil as innovative green candidate for antifungal and antiaflatoxigenic activity in millets with emphasis on cellular and its mode of action

open access: yesFrontiers in Microbiology, 2022
The present study demonstrates first time investigation on encapsulation of Aniba rosaeodora essential oil into chitosan nanoemulsion (AREO-CsNe) with the aim of improvement of its antifungal, and aflatoxin B1 (AFB1) inhibitory performance in real food ...
Bijendra Kumar Singh   +6 more
doaj   +1 more source

COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations

open access: yesFrontiers in Immunology, 2021
The world has entered the second wave of the COVID-19 pandemic, and its intensity is significantly higher than that of the first wave of early 2020. Many countries or regions have been forced to start the second round of lockdowns.
Qian He   +7 more
doaj   +1 more source

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

open access: yesAnnals of the Rheumatic Diseases, 2020
Objectives This integrated analysis presents the safety profile of upadacitinib, a Janus kinase inhibitor, at 15 mg and 30 mg once daily in patients with moderately to severely active rheumatoid arthritis (RA).
S. Cohen   +10 more
semanticscholar   +1 more source

The Adverse Drug Reactions Registered During the Postmarketing Period

open access: yesБезопасность и риск фармакотерапии, 2019
Efficacy, safety and biotransformation features of any drug are fully revealed during widely using. Therefore, postmarketing studies of the pharmacological properties of drugs are an integral component of pharmacovigilance.
E. V. Shubnikova   +8 more
doaj   +1 more source

Analysis of the decisions of foreign regulatory authorities

open access: yesБезопасность и риск фармакотерапии, 2019
Analysis of  recommendations of  foreign regulatory authorities on  the  restriction of  circulation of medicines and/or the  need  for  changes in the  instructions for  their medical use  due  to changes in the safety profile, conducted by experts of ...
Relevant information
doaj   +1 more source

Safety profile of lamotrigine in overdose [PDF]

open access: yesTherapeutic Advances in Psychopharmacology, 2016
Background: Lamotrigine is an anticonvulsant as well as a mood stabilizer. Apart from its established use in the treatment of epilepsy, there has been an expansion of its use in the treatment of mental disorders.
Alibi, A.   +3 more
openaire   +4 more sources

Functional Outcomes and Safety Profile of Trans-Foveal Subthreshold Micropulse Laser in Persistent Central Serous Chorioretinopathy

open access: yesLife, 2023
Our study evaluated visual function changes after subthreshold micropulse laser (SML) treatment in persistent central serous chorioretinopathy (CSC) and SML safety profile. We conducted a prospective study including 31 fovea-involving CSC patients.
Peter Kiraly   +3 more
doaj   +1 more source

Preclinical safety profile of sildenafil [PDF]

open access: yesInternational Journal of Impotence Research, 2004
Sildenafil citrate, marketed as Viagra, for the treatment of erectile dysfunction, has a proven record of safety in humans as predicted by the results of extensive pharmacological and toxicological testing in animals and in vitro, and confirmed by pharmacokinetic exposure data.
D, Abbott   +10 more
openaire   +2 more sources

Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial

open access: yesJournal of the European Academy of Dermatology and Venereology, 2020
Secukinumab has demonstrated sustained long‐term efficacy with a favourable safety profile in various psoriatic disease manifestations in adults.
C. Bodemer   +12 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy